Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Coeptis Therapeutics Holdings Inc (COEPW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/10/2025: COEPW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
0 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
Analysis of Past Performance
Type Stock | Historic Profit -89.12% | Avg. Invested days 14 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/10/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta -0.59 | 52 Weeks Range 0.00 - 0.05 | Updated Date 02/25/2025 |
52 Weeks Range 0.00 - 0.05 | Updated Date 02/25/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -245.55% | Return on Equity (TTM) -1449.7% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 12704886 |
Shares Outstanding - | Shares Floating 12704886 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Coeptis Therapeutics Holdings Inc
Company Overview
History and Background
Coeptis Therapeutics Holdings, Inc. is a pharmaceutical company focused on developing innovative therapies. Founded in 2013, the company has focused on acquiring and developing assets in oncology and other areas. Milestones include acquiring companies to expand portfolio and progress clinical trials. The company has shifted strategy over time with key licensing agreements.
Core Business Areas
- Drug Development: Focuses on developing and commercializing therapies for cancer and other diseases. Utilizes proprietary technology platforms.
- CD38-Directed Therapeutic Antibody: This segment focuses on drug candidate, CD38-GEAR-NK cell therapy. The drug target is CD38, found in abundance in myeloma tumor cells as well as solid tumors.
Leadership and Structure
The company's leadership team consists of a CEO, CFO, and other key executives. The organizational structure includes departments for research and development, clinical operations, and business development.
Top Products and Market Share
Key Offerings
- CD38-GEAR-NK: CD38-GEAR-NK cell therapy is Coeptisu2019 drug candidate that is designed to overcome key limitations of existing CD38-targeted therapies. Coeptis Therapeutics Holdings Inc is currently in clinical trials. Competitors include Darzalex (daratumumab) from Johnson & Johnson.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and regulated, with significant investment in research and development. The industry includes major players such as Johnson and Johnson (JNJ) and Pfizer (PFE). The market for cancer therapies is growing due to the increasing incidence of cancer worldwide.
Positioning
Coeptis Therapeutics Holdings Inc is a smaller player in the pharmaceutical industry, focused on niche markets with innovative therapies. Competitive advantages include proprietary technology platforms and strategic partnerships.
Total Addressable Market (TAM)
The total addressable market for cancer therapies is estimated to be in the hundreds of billions of dollars. Coeptis Therapeutics Holdings Inc aims to capture a portion of this market through the development and commercialization of its therapies.
Upturn SWOT Analysis
Strengths
- Innovative Technology
- Experienced Management Team
- Strategic Partnerships
- Niche Market Focus
Weaknesses
- Limited Financial Resources
- Early Stage Pipeline
- Dependence on Key Personnel
- Limited Market Presence
Opportunities
- Expanding into New Markets
- Acquiring Complementary Technologies
- Securing Regulatory Approvals
- Forming Strategic Alliances
Threats
- Competition from Larger Companies
- Regulatory Hurdles
- Patent Infringement
- Clinical Trial Failures
Competitors and Market Share
Key Competitors
- JNJ
- PFE
- MRK
- BMY
- GILD
Competitive Landscape
Coeptis Therapeutics Holdings Inc faces significant competition from larger pharmaceutical companies with greater resources. The company differentiates itself through innovative technologies and niche market focus.
Growth Trajectory and Initiatives
Historical Growth: Historical growth data unavailable.
Future Projections: Future growth projections data unavailable.
Recent Initiatives: Recent initiatives include focusing on CD38-GEAR-NK cell therapy and other asset acquisitions.
Summary
Coeptis Therapeutics Holdings Inc is a development-stage pharmaceutical company focused on developing innovative therapies. The company's strengths lie in its innovative technology and strategic partnerships. Weaknesses include limited financial resources and early-stage pipeline. It needs to secure funding and achieve clinical trial success to fully realize potential.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Market Reports
Disclaimers:
The data provided is for informational purposes only and should not be considered investment advice. Market share is an estimate and may vary based on source.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Coeptis Therapeutics Holdings Inc
Exchange NASDAQ | Headquaters Wexford, PA, United States | ||
IPO Launch date 2020-12-17 | Co-Founder, Chairman, CEO & Pres Mr. David Mehalick | ||
Sector Healthcare | Industry Biotechnology | Full time employees 4 | Website https://coeptispharma.com |
Full time employees 4 | Website https://coeptispharma.com | ||
Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company has collaboration with Statera BioPharma to develop and commercialize STAT-201 for Crohn's disease; and Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. Coeptis Therapeutics Holdings, Inc. is headquartered in Wexford, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.